Knight Therapeutics Inc.

TSX:GUD.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$11.56 +0.75%

+$0.07 today

Market cap
$1.14B
Beta
0.07
P/E (TTM)
164.6
EPS (TTM)
$0.06
52W Low $5.66High $9.59

Volume 0.04M

Average 0.10M

Returns on capital

Knight Therapeutics Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-0.7%

avg 1.1%

ROIC

-0.2%

avg -0.3%

ROA

-0.5%

avg 1.1%

Analysis

ROIC is currently the strongest return metric at -0.2% versus its period average of -0.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Samira Sakhia

President, Chief Executive Officer & DirectorCAD 1.44M58——

Arvind Utchanah

Chief Financial OfficerCAD 1.12M———

Amal Khouri

Chief Business OfficerCAD 1.06M———

Christine Poulin

General Manager of CanadaCAD 789.22K———

Jonathan Ross Goodman

Executive ChairmanCAD 528.44K57——

Susan Caroline Emblem

Global Vice President of Human ResourcesCAD 482.41K———

Monica Percario

Global Vice President of Regulatory & QualityCAD 480.57K———

Henrique Dias

Global Vice President of MarketingCAD 479.79K———

Leopoldo Bosano

Vice-President of Manufacturing & OperationsCAD 478.92K———

Melanie Groleau

Global Vice President of Medical & Clinical————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+15.3%
+7.0% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at +15.3% over three years. Forward estimates point to Revenue at +7.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Knight Therapeutics Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about GUD.TO's management, answered from reported figures.

Who manages GUD.TO?

Knight Therapeutics Inc. (GUD.TO) lists 10 active executives. The top listed executive is Amal Khouri, Chief Business Officer.